Daniel Ghinn· @creationdaniel · X·· 22 小时前评分70
正文 · 原文
24-hour top trending trials we're tracking at #ESMO26 as we start day 2, based on posts by validated HCPs on social media:
AMPLIFY-7P
TALAPRO-7
NATALEE
PANKU-Breast01
TNBC
PEARL
DeLLphi-305
KEYNOTE-365
For our #ESMO26 platform we're tracking HCP posts about every trial and product in the following tumour types:
#breastcancer
#lungcancer
#ovariancancer
#prostatecancer
#colorectalcancer
...and so can you, with our complimentary access programme during ESMO only - just sign up at http://intelligence.creation.co
14 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：Daniel Ghinn · x.com